StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Raymond James Upgrades Alnylam Pharmaceuticals (ALNY) to Strong Buy
August 3, 2026 7:20 AM
Raymond James analyst Martin Auster upgraded Alnylam Pharmaceuticals (NASDAQ: ALNY) from Outperform to Strong Buy with a price target of ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Hot Comments
Hot Upgrades
Upgrades
Next Articles
Alnylam Pharmaceuticals (ALNY) PT Lowered to $450 at Barclays
August 3, 2026 6:39 AM
Alnylam Pharmaceuticals (ALNY) PT Lowered to $375 at JPMorgan
July 31, 2026 9:20 AM
Alnylam Pharmaceuticals (ALNY) PT Lowered to $316 at Wells Fargo
July 31, 2026 8:35 AM
Alnylam Pharmaceuticals (ALNY) PT Lowered to $350 at Oppenheimer
July 31, 2026 8:11 AM
Alnylam Pharma. (ALNY) PT Lowered; RBC Capital: 'Tough Update But Stock Reaction Looks Overdone'
July 31, 2026 8:09 AM
Alnylam Pharmaceuticals (ALNY) PT Lowered to $318 at Stifel
July 31, 2026 8:08 AM
Alnylam Pharmaceuticals (ALNY) PT Lowered to $300 at Morgan Stanley
July 31, 2026 8:00 AM
H.C. Wainwright Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
July 31, 2026 6:41 AM
Form 10-Q ALNYLAM PHARMACEUTICALS, For: Jun 30
July 30, 2026 8:11 AM
Alnylam Pharma (ALNY) Tops Q2 EPS by 24c ; Offers Guidance
July 30, 2026 8:09 AM
Form 8-K ALNYLAM PHARMACEUTICALS, For: Jul 30
July 30, 2026 8:06 AM
